Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 2 |
2022 | 3 |
2023 | 3 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin.
J Neurol. 2023 Feb;270(2):788-796. doi: 10.1007/s00415-022-11395-2. Epub 2022 Oct 5.
J Neurol. 2023.
PMID: 36195775
Free PMC article.
No Secondary Treatment Failure during Incobotulinumtoxin-A Long-Term Treatment Demonstrated by the Drawing of Disease Severity.
Hefter H, Brauns R, Ürer B, Rosenthal D, Albrecht P, Samadzadeh S.
Hefter H, et al. Among authors: urer b.
Toxins (Basel). 2023 Jul 12;15(7):454. doi: 10.3390/toxins15070454.
Toxins (Basel). 2023.
PMID: 37505723
Free PMC article.
Item in Clipboard
Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study.
Hefter H, Schomaecker I, Schomaecker M, Ürer B, Brauns R, Rosenthal D, Albrecht P, Samadzadeh S.
Hefter H, et al. Among authors: urer b.
Toxins (Basel). 2023 Jun 30;15(7):431. doi: 10.3390/toxins15070431.
Toxins (Basel). 2023.
PMID: 37505701
Free PMC article.
Item in Clipboard
Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure.
Hefter H, Ürer B, Brauns R, Rosenthal D, Meuth SG, Lee JI, Albrecht P, Samadzadeh S.
Hefter H, et al. Among authors: urer b.
Toxins (Basel). 2022 Jan 6;14(1):44. doi: 10.3390/toxins14010044.
Toxins (Basel). 2022.
PMID: 35051021
Free PMC article.
Item in Clipboard
The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia.
Hefter H, Ürer B, Brauns R, Rosenthal D, Meuth SG, Lee JI, Albrecht P, Samadzadeh S.
Hefter H, et al. Among authors: urer b.
J Neurol. 2022 Nov;269(11):5991-6002. doi: 10.1007/s00415-022-11235-3. Epub 2022 Jul 17.
J Neurol. 2022.
PMID: 35842881
Free PMC article.
Item in Clipboard
Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study.
Hefter H, Brauns R, Ürer B, Rosenthal D, Albrecht P.
Hefter H, et al. Among authors: urer b.
J Neurol. 2020 May;267(5):1340-1347. doi: 10.1007/s00415-019-09681-7. Epub 2020 Jan 20.
J Neurol. 2020.
PMID: 31960136
Free PMC article.
Item in Clipboard
Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature.
Samadzadeh S, Ürer B, Brauns R, Rosenthal D, Lee JI, Albrecht P, Hefter H.
Samadzadeh S, et al. Among authors: urer b.
Toxins (Basel). 2020 Aug 4;12(8):499. doi: 10.3390/toxins12080499.
Toxins (Basel). 2020.
PMID: 32759685
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite